Mathias Oelke's most recent trade in Neximmune Inc was a trade of 115,051 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 4, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 115,051 | 115,051 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 115,051 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 81,100 | 81,100 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 60,000 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 47,379 | 47,379 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 47,379 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 38,750 | 38,750 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 31,948 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 31,948 | 31,948 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 21,250 | 21,250 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 19,905 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 15,793 | 15,793 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 15,793 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 12,855 | 12,855 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 7,050 | 7,050 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 4,755 | 4,755 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Apr 2023 | 4,755 | 0 | - | - | Stock Option (right to buy) | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2022 | 126,100 | 134,023 | - | 0 | Common Stock | |
| Neximmune Inc | Mathias Oelke | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) |